| Nimotuzumab: beyond the EGFR signaling cascade inhibition Z Mazorra, L Chao, A Lavastida, B Sanchez, M Ramos, N Iznaga, ... Seminars in oncology 45 (1-2), 18-26, 2018 | 62 | 2018 |
| Upregulation of HLA class I expression on tumor cells by the anti-EGFR antibody nimotuzumab G Garrido, A Rabasa, C Garrido, L Chao, F Garrido, ÁM García-Lora, ... Frontiers in pharmacology 8, 595, 2017 | 34 | 2017 |
| Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms G Garrido, A Rabasa, C Garrido, A Lopez, L Chao, ÁM García-Lora, ... Oncogene 33 (24), 3129-3139, 2014 | 34 | 2014 |
| Nimotuzumab-mediated antibody-dependent cellular cytotoxicity activity on target tumor cell lines depends on the expression level of the epidermal growth factor receptor L Chao, D Pérez, B Sánchez Biotecnología Aplicada 34 (1), 1201-1205, 2017 | 4 | 2017 |
| Binding properties and biological activity of a novel therapeutic monoclonal antibody directed toward HER2 antigen R Blanco, LA Alcalde, M Ramal, E Dominguez, L Chao, D Pérez, ... Acta Pharmaceutica, 2019 | 1 | 2019 |
| Citotoxicidad celular dependiente de anticuerpos inducida por el nimotuzumab en líneas tumorales depende de los niveles de expresión del receptor del factor de crecimiento … L Chao, D Pérez, B Sánchez Biotecnología Aplicada 34 (1), 1201-1205, 2017 | | 2017 |
